Paloma Partners’s Xeris Biopharma Holdings XERS Stock Holding History

Paloma Partners’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,066	Closed	-$29K	–	2299
2021 Q4	$29K	Buy	+10,066	New	+$21.7K	﹤0.01%	1846

Other funds holding XERS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's XERS Position: Q1 2022 in Review

Paloma Partners sold out of Xeris Biopharma Holdings (XERS) in Q1 2022, closing a stake of 10,066 shares — an estimated $29K sold.

Paloma Partners first reported a position in XERS in Q4 2021 and held it in 1 quarter. The position peaked at $29K in Q4 2021. 103 funds tracked by Wall St. Rank hold XERS as of Q1 2022.

Paloma Partners reported no remaining Xeris Biopharma Holdings position as of Q1 2022 after selling out during the quarter.
Paloma Partners sold 10,066 Xeris Biopharma Holdings shares in Q1 2022, an estimated $29K.
Paloma Partners first reported a position in Xeris Biopharma Holdings in Q4 2021 and held it in 1 quarter.
Paloma Partners's Xeris Biopharma Holdings position peaked at $29K in Q4 2021.
103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2022.

Based on Paloma Partners's 13F filing for Q1 2022, filed 16 May 2022.